Rationale:Pituitary apoplexy(pa)is a rare endocrine emergency that requires prompt diagnosis and *** fever-induced-thrombocytopenia may rarely predispose to ***’s Concern:A 58-year-old male patient having known pitui...
详细信息
Rationale:Pituitary apoplexy(pa)is a rare endocrine emergency that requires prompt diagnosis and *** fever-induced-thrombocytopenia may rarely predispose to ***’s Concern:A 58-year-old male patient having known pituitary macroadenoma presented to the emergency department with fever,a sudden onset severe headache,and altered ***:Pituitary apoplexy caused by dengue ***:Conservative management with fluids,mannitol,dexamethasone and symptomatic ***:The patient responded well to the treatment and was discharged ***:Although dengue hemorrhagic fever is a rare cause of pituitary apoplexy,it should be considered if a patient presents with headache and altered sensorium,and prompt initiation of treatment is crucial to prevent fatality and neuro-ophthalmic deficits.
Background: Nepal is one of the fastest urbanizing countries in South Asia and is facing the consequences of urban lifestyle leading to obesity and metabolic syndrome. Type 2 diabetes mellitus (T2DM) is currently a hi...
详细信息
Background: Nepal is one of the fastest urbanizing countries in South Asia and is facing the consequences of urban lifestyle leading to obesity and metabolic syndrome. Type 2 diabetes mellitus (T2DM) is currently a high-burden disease in Nepal with a prevalence of 8.4%. Of these 8% - 18% patients are on insulin and 42% patients were reported to have uncontrolled diabetes in the past year. This suggests a need for better therapy options in terms of efficacy and safety. The current study was designed to investigate the effects of Insulin glargine-based therapy in Nepalese with T2DM who could not achieve adequate glycemic control with oral and non-glargine-insulin therapy. Methods: This is a prospective, multi-centric, single arm and post marketing observational study to assess the safety and effectiveness of Glaritus®(Wockhardt’s Insulin Glargine) in 52 T2DM patients from 3 (three) different study sites in Nepal (Bharatpur, Kathmandu and Pokhra) from September 2015 to December 2016. The primary objective of the study was to evaluate the safety of Glaritus®, mainly in terms of hypoglycemia, renal function tests and liver function tests. The secondary objectives were to evaluate the effectiveness of Glaritus®in terms of percentage of patients achieving HbA1c goal of less than 7%, mean changes in HbA1c & fasting plasma glucose (FPG) levels from baseline till the end of study. Results: 3.85% of subjects experienced hypoglycemia during first 3 months of therapy whereas 1.92% had similar experience in next 3 months of therapy. The mean HbA1c values reduced from 9.16% to 7.15% at the end of study. 21.05% of the enrolled subjects achieved the goal of HbA1c ®was well tolerated by the study patients. Conclusion: In patients with type 2 diabetes mellitus inadequately controlled on oral hypoglycemic agents and/or insulin, initiation with Glaritus®significantly improved glycemic control with good tolerability and acceptability. This analysis in T2DM Nepalese pa
最近,5项具有里程碑意义的多中心、前瞻性、随机、开放标签、盲法终点的临床试验证实,在伴有颅内大血管闭塞的急性缺血性卒中(acute ischemic stroke,AIS)患者中,应用机械血栓切除术进行血管内治疗具有显著的临床获益。血管和介入神经病学学会(Society of Vascular and Interventional,SVIN)任命了一个专业写作委员会来总结这些新证据,并就如何应用这些数据指导AIS患者的急诊血管内治疗提出了推荐意见。
暂无评论